Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- About
AZN 
AstraZeneca PLC ADR (AZN)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/08/2025: AZN (2-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Number of Analysts
12 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $96.86
1 Year Target Price $96.86
| 6 | Strong Buy |
| 5 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 18.76% | Avg. Invested days 42 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  2.0 |
| Profits based on simulation | Last Close 12/08/2025 |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 283.02B USD | Price to earnings Ratio 30.33 | 1Y Target Price 96.86 |
Price to earnings Ratio 30.33 | 1Y Target Price 96.86 | ||
Volume (30-day avg) 12 | Beta 0.17 | 52 Weeks Range 60.83 - 94.02 | Updated Date 12/9/2025 |
52 Weeks Range 60.83 - 94.02 | Updated Date 12/9/2025 | ||
Dividends yield (FY) 1.74% | Basic EPS (TTM) 3.01 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 16.17% | Operating Margin (TTM) 24.11% |
Management Effectiveness
Return on Assets (TTM) 9.06% | Return on Equity (TTM) 21.67% |
Valuation
Trailing PE 30.33 | Forward PE 17.73 | Enterprise Value 305543262616 | Price to Sales(TTM) 4.87 |
Enterprise Value 305543262616 | Price to Sales(TTM) 4.87 | ||
Enterprise Value to Revenue 5.26 | Enterprise Value to EBITDA 17.02 | Shares Outstanding 3100567054 | Shares Floating 1543291530 |
Shares Outstanding 3100567054 | Shares Floating 1543291530 | ||
Percent Insiders - | Percent Institutions 16.73 |
Upturn AI SWOT
AstraZeneca PLC ADR
Company Overview
History and Background
AstraZeneca PLC is a British multinational pharmaceutical and biopharmaceutical company, formed in 1999 through the merger of Astra AB of Sweden and Zeneca Group PLC of the United Kingdom. It is one of the largest pharmaceutical companies in the world by revenue and market capitalization. The company has a rich history of scientific innovation and has been at the forefront of developing treatments for major diseases.
Core Business Areas
- Oncology: Focuses on developing and delivering innovative cancer medicines across a range of tumor types, including breast, ovarian, prostate, lung, and hematological cancers. Key areas include targeted therapies, immunotherapy, and antibody-drug conjugates.
- Cardiovascular, Renal & Metabolism (CVRM): Develops medicines to treat cardiovascular diseases, chronic kidney disease, and diabetes. This segment aims to reduce the burden of these chronic conditions.
- Respiratory & Immunology: Provides treatments for respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD), as well as autoimmune diseases like rheumatoid arthritis and lupus.
- Vaccines & Immune Therapies: While primarily known for other segments, AstraZeneca has also been involved in developing and supplying vaccines and immune therapies, notably during the COVID-19 pandemic.
- Rare Diseases: Invests in the development of treatments for rare diseases, addressing unmet medical needs in areas like cystic fibrosis and rare blood disorders.
Leadership and Structure
AstraZeneca is a publicly traded company with a Board of Directors overseeing its strategic direction. The executive leadership team is responsible for day-to-day operations, including research and development, manufacturing, marketing, and sales. The company operates globally with a decentralized structure that allows for regional autonomy.
Top Products and Market Share
Key Offerings
- Description: A targeted therapy for non-small cell lung cancer (NSCLC) with specific EGFR mutations. It has achieved significant market share in its indication and is a major revenue driver. Competitors include other EGFR inhibitors like Erlotinib (Tarceva) and Afatinib (Gilotrif).
- Product Name: Tagrisso (osimertinib)
- Description: An immunotherapy (PD-L1 inhibitor) used to treat certain types of lung cancer and bladder cancer. It plays a crucial role in AstraZeneca's oncology portfolio. Competitors include Keytruda (pembrolizumab) and Opdivo (nivolumab).
- Product Name: Imfinzi (durvalumab)
- Description: A medication for type 2 diabetes, heart failure, and chronic kidney disease. It has shown significant growth and market penetration across multiple indications. Competitors include other SGLT2 inhibitors like Jardiance (empagliflozin) and Invokana (canagliflozin).
- Product Name: Farxiga (dapagliflozin)
- Description: A PARP inhibitor used in the treatment of certain ovarian, breast, prostate, and pancreatic cancers. It is a key oncology product with growing market share. Competitors include other PARP inhibitors like Rucaparib (Rubraca) and Niraparib (Zejula).
- Product Name: Lynparza (olaparib)
- Description: An inhaled corticosteroid and long-acting beta-agonist combination for the treatment of asthma and COPD. It is a well-established product in the respiratory market. Competitors include Advair (fluticasone/salmeterol) and Breo Ellipta (fluticasone furoate/vilanterol).
- Product Name: Symbicort (budesonide/formoterol)
Market Dynamics
Industry Overview
The global pharmaceutical industry is characterized by intense competition, significant R&D investment, stringent regulatory oversight, and a growing demand for innovative treatments for chronic and rare diseases. Key trends include the rise of biologics, personalized medicine, and the increasing importance of emerging markets.
Positioning
AstraZeneca is positioned as a leading global biopharmaceutical company with a strong focus on innovation, particularly in oncology, cardiovascular, renal & metabolism, and respiratory & immunology. Its competitive advantages lie in its robust R&D pipeline, established global commercial infrastructure, and strategic acquisitions.
Total Addressable Market (TAM)
The global pharmaceutical market is valued in the trillions of US dollars and is expected to continue growing. AstraZeneca is well-positioned to capture a significant share of this TAM through its diverse portfolio and ongoing pipeline development, particularly in key therapeutic areas with high unmet needs.
Upturn SWOT Analysis
Strengths
- Strong and diverse R&D pipeline with significant potential for future drug approvals.
- Leading positions in key therapeutic areas like oncology and CVRM.
- Global commercialization capabilities and established market access.
- Significant investment in R&D and commitment to scientific innovation.
- Strategic acquisitions and collaborations to bolster pipeline and market reach.
Weaknesses
- Reliance on a few blockbuster drugs, making it susceptible to patent expirations and competition.
- High R&D costs and the inherent risks associated with drug development.
- Potential for regulatory delays or rejections of new drug applications.
- Complex global supply chain management.
Opportunities
- Growing demand for innovative treatments for chronic diseases and rare conditions.
- Expansion into emerging markets with increasing healthcare spending.
- Leveraging advancements in artificial intelligence and big data in drug discovery.
- Strategic partnerships and collaborations to accelerate R&D and market entry.
- Pipeline advancements in oncology and immunology.
Threats
- Increasing price pressures and government regulation on drug pricing.
- Intensifying competition from both established players and emerging biotech firms.
- Patent cliffs and the genericization of key products.
- Adverse outcomes in clinical trials or regulatory reviews.
- Geopolitical uncertainties and their impact on global markets.
Competitors and Market Share
Key Competitors
- Pfizer Inc. (PFE)
- Novartis AG (NVS)
- Roche Holding AG (RHHBY)
- Merck & Co., Inc. (MRK)
- Johnson & Johnson (JNJ)
Competitive Landscape
AstraZeneca excels in its focused therapeutic areas, particularly oncology, where it has a strong portfolio and pipeline. Its competitive advantage lies in its targeted approach to drug development and strong clinical trial execution. However, it faces intense competition from diversified pharmaceutical giants with broader portfolios and significant R&D budgets.
Major Acquisitions
Alexion Pharmaceuticals
- Year: 2021
- Acquisition Price (USD millions): 39000
- Strategic Rationale: To significantly expand AstraZeneca's presence in rare diseases, adding Alexion's expertise in complement-mediated diseases and its blockbuster drug Soliris.
Amolyt Pharma
- Year: 2023
- Acquisition Price (USD millions): 1050
- Strategic Rationale: To strengthen AstraZeneca's rare disease portfolio, particularly in endocrinology, by adding Amolyt's lead candidate for hypoparathyroidism.
Growth Trajectory and Initiatives
Historical Growth: AstraZeneca has demonstrated strong historical growth, driven by successful product launches, strategic acquisitions, and a focus on high-growth therapeutic areas. The company has consistently expanded its revenue and profitability.
Future Projections: Future growth projections for AstraZeneca are generally positive, supported by its robust pipeline, especially in oncology and CVRM, and expansion into new markets. Analyst estimates often forecast continued revenue and earnings growth.
Recent Initiatives: Recent strategic initiatives include ongoing clinical trials for novel therapies, expansion of manufacturing capabilities, strategic partnerships for drug development and commercialization, and a continued focus on R&D productivity.
Summary
AstraZeneca PLC ADR is a strong global biopharmaceutical company with a robust R&D pipeline and leading positions in key therapeutic areas like oncology and CVRM. Its recent acquisitions, like Alexion, have significantly expanded its rare disease segment. The company faces challenges from intense competition and pricing pressures, but its focus on innovation and unmet medical needs positions it for continued growth.
Similar Stocks
Sources and Disclaimers
Data Sources:
- AstraZeneca PLC Investor Relations Reports
- Financial News Outlets (e.g., Bloomberg, Reuters)
- Pharmaceutical Industry Analysis Reports
- SEC Filings (e.g., 10-K, 10-Q)
Disclaimers:
This analysis is based on publicly available information and is for informational purposes only. It does not constitute investment advice. Market share data and financial metrics are estimates and subject to change. Users should conduct their own due diligence before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About AstraZeneca PLC ADR
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 1993-05-12 | CEO & Executive Director Mr. Pascal Claude Roland Soriot D.V.M., M.B.A. | ||
Sector Healthcare | Industry Drug Manufacturers - General | Full time employees 94300 | Website https://www.astrazeneca.com |
Full time employees 94300 | Website https://www.astrazeneca.com | ||
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Crestor, Seloken, Lokelma, Roxadustat, Andexxa, Wainua, Symbicort, Fasenra, Pulmicort, Breztri/Trixeo, Saphnelo, Tezspire, Airsupra, Ultomiris, Soliris, Strensiq, Koselugo, Kanuma, Atacand, Plendil, Modip, Splendil, Munobal, Flodil, Komboglyze, Qtern, Byetta, XIGDUO, Accolate, Accoleit, Vanticon, Beyfortus, Synagis, FluMist, tixagevimab and cilgavimab, and sipavibart. It also provides Bricanyl Respules, Eklira Genuair/Tudorza/Bretaris, Bricanyl Turbuhaler, Rhinocort, Bevespi Aerosphere, Daliresp/Daxas, Oxis Turbuhaler, Breztri Aerosphere, Duaklir Genuair, Kavigale, Evusheld, Fluenz/FluMist, and Voydeya. The company offers its products for ocology, cardiovascular, renal and metabolism, respiratory & immunology, vaccines and immune, and therapies rare diseases. It serves primary and specialty care physicians through distributors and local representative offices in the United Kingdom, the United States, Europe, and Asia. It has a strategic agreement with Tempus to develop the largest multimodal foundation model in oncology. The company has a collaboration agreement with IonQ, Inc. for the development of quantum-accelerated computational chemistry workflow for healthcare, life sciences, and chemistry; a strategic research collaboration with CSPC Pharmaceutical Group Limited to advance the discovery and development of novel oral candidates, with the potential to treat diseases across multiple indications; and collaboration Revna Biosciences for lung cancer treatment. AstraZeneca PLC was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.